Effect of novel mucoadhesive buccal patches of carvedilol on isoprenaline-induced tachycardia

Navneet Verma, Pronobesh Chattopadhyay

Department of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, Defence Research Laboratory, DRDO, Tezpur, Assam, India

J. Adv. Pharm. Technol. Res.

INTRODUCTION

The buccal mucosa offers many advantages because of its smooth and relatively immobile surface and its suitability for the placement of controlled-release system, which is well-accepted by patients. The buccal mucosa is a useful route for the treatment of either local or systemic therapies overcoming the drawbacks of conventional administration routes. These routes can bypass the first-pass effect and exposure of the drugs to the gastrointestinal fluids. Bioadhesive polymer can significantly improve the performance of many drugs, as they are having prolonged contact time with these tissues. These patient compliance controlled drug delivery products have improved drug bioavailability at suitable cost.

The oral mucosa has a rich blood supply. Drugs are absorbed from the oral cavity through the oral mucosa, and transported through the deep lingual or facial vein, internal jugular vein, and brachiocephalic vein into the systemic circulation.

Carvedilol is a non-selective beta blocker used in the treatment of mild to moderate congestive heart failure (CHF). It blocks β₁ and β₂ adrenergic receptors as well as the α₁ adrenergic receptors. Carvedilol is rapidly and extensively absorbed following oral administration. The absolute bioavailability of carvedilol is approximately 25%. Plasma levels peak approximately one hour after an oral dose.

Chitosan is a natural polymer obtained by de-acetylation of chitin. Chitin is the second most abundant polysaccharides in nature after cellulose. It is a biologically safe, non-toxic, biocompatible, and biodegradable polysaccharide.

Being a bioadhesive polymer and having antibacterial activity, chitosan is a good candidate for site-specific drug delivery.
Buccal device of carvedilol is also used in case of tachycardia produced by isoprenaline, and examine the usefulness of the device in suppressing isoprenaline-induced tachycardia in rabbits.[18]

MATERIALS AND METHODS

Phenobarbitone (Samarth life Sci. Pvt. Ltd., Mumbai), Carvedilol (Aurobindo Pharma Ltd. Medak), Isoprenaline (Samarth life Sci. Pvt. Ltd., Mumbai), Chitosan (Sigma Aldrich, Mumbai), polyvinyl alcohol (Qualigens fine chemicals, Mumbai), sodium carboxymethyl cellulose (Qualigens fine chemicals, Mumbai) were used. Other chemicals were of analytical grade.

Drug-polymer compatibility study
Drug-polymer interaction was observed by IR spectrophotometry and differential scanning microscopy (DSC). An FTIR study of pure carvedilol and physical mixture of carvedilol and polymers were recorded. For DSC study, thermogram was recorded from 38°C to 450°C at the heating rate 10°C/min under a constant flow of an inert nitrogen gas atmosphere with the flow rate of 20 ml/min.[19]

Preparation of mucoadhesive buccal patches of carvedilol
Patches of carvedilol containing different polymer proportions were prepared by the solvent casting method. For chitosan patches, calculated amount of chitosan was dissolved in 1.5% (v/v) acetic acid, and for sodium carboxymethyl cellulose patches, calculated amount of sodium carboxymethyl was dissolved in purified water under constant stirring for 12 h. For polyvinyl alcohol patches, PVA was dissolved in hot water (80-100°C) under constant stirring for 08 h. In resultant viscous solution 5% glycerol as plasticizer and calculated amount of drug solution was added [Table 1]. The resultant viscous solution was left to stand until all air bubbles disappeared.[20] The solution was poured into a clean, dry, glass petri dish and left to dry at room temperature. The dried films were carefully removed from the petri dish, checked for any imperfection or bubbles, and cut into 10 mm (1.0 cm) diameter patches. The samples were packed in aluminum foil and stored in a glass container maintained at room temperature.[21]

Content uniformity
Drug content uniformity was determined by dissolving the CR patch by homogenization in 100 ml of phosphate buffer (pH 6.8) for 8 h under occasional shaking.[22] The drug content was then determined after proper dilution at 285 nm using a UV-spectrophotometer (Shimadzu, Japan).

Patch thickness and weight variation
The thickness of the patch was measured using screw gauge with a least count of 0.01 mm at different spots of the patch. Weight variation was tested in 10 different randomly selected patches using electronics single pan balance.[23]

Surface pH
For determination of surface pH, three buccal patches of each formulation were allowed to swell for 2 h on the surface of agar plate (2% w/v). The surface pH was measured by using a pH paper placed on the surface of swollen patch.[24]

% Swelling
After determination the initial patch weight, the samples were allowed to swell on the surface of agar plate (2% w/v) kept in an incubator at 37 ± 1°C.[25] At regular interval of one-hour (for 6 h), the weight of the patch was determined, and radial swelling was calculated as

\[ S_D (%) = \frac{(W_t - W_0)}{W_0} \times 100 \]

\( S_D (%) \) is the percent swelling obtained by the weight method, \( W_t \) is the weight of the swollen patch after time \( t \), \( W_0 \) is the initial patch weight at time zero.

Folding endurance
For the determination of folding endurance, the patches were folded repeatedly at the same place till it broken; the number of times the film could be folded at the same place without breaking gave the value of the folding endurance.[26]

Residence time
The in vitro residence time was determined by a locally modified USP disintegration apparatus using phosphate buffer of pH 6.8 maintained at 37 ± 0.5°C as medium. A segment of pig intestinal mucosa was glued to the surface of glass slab, vertically attached to the apparatus. The buccal patch was hydrated from one surface using 10 µl isotonic phosphate buffer, and then hydrated surface was brought into contact with the mucosal membrane.[27] The glass slab was allowed to move up and down, and then the time necessary for complete erosion or detachment of the patch from the mucosal surface was recorded.

| Table 1: Compositions of different buccal patches containing carvedilol |
|-----------------|-------|-------|-------|-------|
| Patch code      | Chitosan (%) | NaCMC    | PVA (%) | Glycerol (%) |
| CC-1            | 1.0       | -       | -       | 5.0       |
| CC-2            | 2.0       | -       | -       | 5.0       |
| CC-3            | 3.0       | -       | -       | 5.0       |
| SC-1            | -         | 1.0     | -       | 5.0       |
| SC-2            | -         | 2.0     | -       | 5.0       |
| SC-3            | -         | 3.0     | -       | 5.0       |
| PC-1            | -         | -       | 8.0     | 5.0       |
| PC-2            | -         | -       | 10.0    | 5.0       |
| PC-3            | -         | -       | 12.0    | 5.0       |

Each formulation contained 2% w/v carvedilol
**In vitro release study**
Drug release from the buccal patches was studied using USP type I dissolution test apparatus. Patches (10 mm diameter) were cut, and an impermeable backing membrane on one side of the patch. The assembly for release studies was prepared by placing the patch in contiguity with cellulose acetate dialysis membrane such that the drug release from the patch diffuses through dialysis membrane. This assembly was placed in dissolution apparatus containing 500 ml of phosphate buffer (pH 6.8) and rotating at 50 rpm at 37 ± 0.5°C. Eight samples (5 ml) were collected after every one hour and diluted with phosphate buffer (pH 6.8), 2 ml of which was analyzed spectrophotometrically (UV-1800, Shimadzu, Japan) at 285 nm.[27] The volume of sample collected was replaced by same volume of fresh phosphate buffer to maintain the sink condition.

**Scanning electron microscopy**
Optimized formulations (CC-2, SC-3, and PC-2) morphology was characterized by scanning electron microscopy. The images were captured on a black and white 35 mm film.[28]

**Pharmacodynamic study**
Healthy albino rabbits of either sex (2.5 to 5.0 kg) were selected for the study. Institution’s animal ethics committee (IAEC) permission was obtained prior to start the study. Rabbits were anaesthetized by intraperitoneal administration of 30 mg/kg of phenobarbitone sodium in sterile normal saline, and the anesthesia was maintained by administering additional phenobarbitone sodium at a dose of 6 mg/kg per hour. Electrocardiograph electrodes (stainless steel needles) were set subcutaneously (one each in right and left forelegs, and right and left hind legs). Lead I or Lead II was used for recording ECG on a physiograph. The chart speed was kept at 5 mm/sec. Heart rate was determined by counting the “R-waves” of the ECG.[29]

**Administration of carvedilol (i.v, oral and buccal patch)**
Normal heart rate of the rabbit was recorded before administration of isoprenaline. Two i.v slow infusion of a standard dose of isoprenaline (0.25 µg/kg) were given at interval of 30 min, and heart rate was recorded. For i.v route[30] study, 100, 200 and 300 µg/kg body weight of carvedilol was administered for 30 sec through central or marginal ear vein. For oral dose, 1, 2 and 4 µg/kg body weight was administered as a bolus via an oral catheter, and similarly for the buccal route, the patch was stuck in the upper oral mucosa after wiping the site with tissue paper. In all the cases, the dose of isoprenaline (0.25 µg/kg) was administered at 5, 30, 60, 120, 180, and 240 min after every CR administration. Heart rate (beats/min) was recorded at 30 sec before and 20 min (4 × 30 sec) after isoprenaline administration. The difference in heart rate before and after each isoprenaline injection was determined.

**Analysis of % inhibition of Isoprenaline-induced tachycardia**
The percentage inhibition of isoprenaline-induced tachycardia was calculated by:

\[
\% \text{Inhibition} = \left(\frac{HR_0 - HR}{HR_0}\right) \times 100
\]

Where \(HR_0\) was number of heart beats increased by isoprenaline before CR administration, and \(HR\) was the number of heart beats increased by isoprenaline after CR administration.

**RESULTS**

**Fourier transform infra red analysis**
In FTIR, spectrum of pure carvedilol shows peaks at 3346.11 of N-H stretching, 3169.05 and 3061.08 peaks are due to C-H and O-H of aromatic ring. Peak of C=O bonded at 1022.80. For PVA, the peaks at 3352 were due to O-H stretching, at 2796 due to –CH2, while at 1415 and 1097 were due to C-O group of PVA. In the spectra of NaCMC, the peaks at 3470 were due to O-H stretching, at 2923 due to C-H stretching, at 1415 due to CH2 stretching, at 1310 due to O-H bending vibration, and at 1080 due to CH2-O-CH2.

The IR spectra of carvedilol, chitosan, NaCMC, PVA, and drug loaded patches showed no evidence of interaction as all the major peaks were found intact or exhibited very minor shift in frequencies.

**Differential scanning calorimetric**
Thermogram of carvedilol showed a broad endothermic peak at 117°C suggesting the melting of the drug, whereas the peak at 317°C indicated the thermal degradation of drug. In the DSC thermogram of chitosan, the endothermic peak at 61°C, for PVA endothermic peak at 215°C and for NaCMC exothermic peak at 332°C was observed.

**Physiochemical properties**
In case of physiochemical properties of CR, loaded patches were presented in Table 2. The content uniformity of chitosan patch was found to be 99.25 ± 2.01, 98.97 ± 1.52, 98.50 ± 1.20, while for NaCMC and PVA patches, it was 97.88 ± 0.05, 98.65 ± 1.40, 97.74 ± 1.57 and 97.12 ± 1.06, 99.00 ± 1.10, 98.20 ± 0.22, respectively. The patch thickness of the patches was measured with the help of screw gauge and was in the range 1.01-1.07 mm, 0.85-0.89 mm, and 1.07-1.09 mm for Chitosan, NaCMC, and PVA patches. The weight of the patches also varies, and it was 117 ± 0.22 - 123 ± 0.19, 107 ± 0.05 - 114 ± 0.04, and 134 ± 0.87 - 138 ± 0.28 for chitosan, NaCMC, and PVA patches. Surface pH of all formulations was found to be between 5.5 and 7.0. The folding endurance of all the patches was found more than 300.
% Swelling
Swelling of CR-loaded patches is presented in Figure 1. The values are as CC-1 > CC-2 > CC-3, SC-1 > SC-2 > SC-3, PC-1 > PC-2 > PC-3, for chitosan, NaCMC, and PVA patches.

Residence time study
Residence properties of CR patches on mucosa are presented in Table 3 and Figure 2. The residence time for CC-1, CC-2, and CC-3 was 10.0 ± 2.44, 12.0 ± 0.63, and 12.5 ± 0.18. While for SC-1, SC-2, SC-3 and PC-1, PC-2, PC-3 was 6.5 ± 3.1, 8.0 ± 0.55, 11.0 ± 0.42 and 7.0 ± 2.3, 11.5 ± 0.11, 13.5 ± 0.58, respectively.

In vitro release study
The values of CR in vitro release study are shown in Figure 3. In 8 hrs, maximum 94.75 ± 0.70%, 85.50 ± 0.20%, and 89.65 ± 3.30% CR was released from CC-2, SC-3, and PC-2 patches, and the minimum amount was release from CC-3 (65.30 ± 3.80%), SC-1 (64.12 ± 2.50%), and PC-1 (51.28 ± 1.35%), respectively. Release kinetics of drug of different formulation follows zero order ($R^2 = 0.950-0.997$), first order ($R^2 = 0.8505-0.9524$), Higuchi model ($R^2 = 0.8570-0.9469$), and Koresmeyer-Peppas equation. Different formulations and their release kinetic models with regression co-efficient and n values are reported in Table 4.

Scanning electron microscopy study
The Scanning Electron Microscopy (SEM) study of optimized batch was found at different set. The SEM photographs of optimized patches (CC-2, SC-3, and PC-2) are shown in Figure 4.

Pharmacodynamic study
In vivo pharmacodynamic study was conducted in rabbit by measuring the inhibition of isoprenaline-induced tachycardia. The normal heart rate of rabbit was 180 ± 20 beats per minutes. Injection of isoprenaline at a dose of 0.25 µg/kg increases the heart rate by 85 ± 20 beats per minutes above the normal heart rate. Administration of CR reduces the increased heart rate through competitive antagonism.

Table 2: Physiochemical properties of mucoadhesive buccal patches containing carvedilol

| Patch code | Content uniformity (%)* | Patch thickness (mm)** | Weight variation (mg)** | Surface pH* | Folding endurance* |
|------------|------------------------|------------------------|-------------------------|-------------|-------------------|
| CC‑1       | 99.25±2.01             | 1.02±0.01              | 117±0.22                | 5.5         | >300              |
| CC‑2       | 98.97±1.52             | 1.01±0.01              | 119±0.15                | 5.5         | >300              |
| CC‑3       | 98.50±1.20             | 1.07±0.02              | 123±0.19                | 5.5         | >300              |
| SC‑1       | 97.88±0.05             | 0.89±0.011             | 107±0.05                | 5.5         | >300              |
| SC‑2       | 98.65±1.40             | 0.87±0.045             | 111±0.44                | 5.5         | >300              |
| SC‑3       | 98.74±1.57             | 0.85±0.01              | 114±0.04                | 5.5         | >300              |
| PC‑1       | 97.12±1.06             | 1.09±0.013             | 134±0.87                | 7.0         | >300              |
| PC‑2       | 99.00±1.10             | 1.07±0.027             | 136±0.021               | 7.0         | >300              |
| PC‑3       | 98.20±0.22             | 1.09±0.019             | 138±0.28                | 7.0         | >300              |

*All values represent mean±SD (n=3), **All values represent mean±SD (n=10), >more than

Figure 1: % Swelling of chitosan, NaCMC, and PVA patches containing carvedilol
Intravenous administration of CR
The effect of intravenous (i.v.) CR on the isoprenaline-induced tachycardia in rabbits and the pharmacodynamic parameters such as Emax, Tmax, and T50% were derived from the time versus percent inhibition in heart rate curves and are summarized in Table 5.

The results indicated the dose-dependent increase in the magnitude of % inhibition and duration of effect of CR after IV administration. CR at a dose of IV-1 (100 µg/kg) and IV-2 (200 µg/kg) produced a maximum of 52.75 ± 5.40 and 72.33 ± 1.20 percent inhibition of isoprenaline-induced tachycardia at 5 min, respectively, after IV injection, whereas CR at a dose of IV-3 (300 µg/kg) produced almost total inhibition of isoprenaline-induced tachycardia i.e. 89.80 ± 2.50 at 5 mins.

The inhibitory effect of IV CR gradually decreases, and at the end of 4 hrs, the effect observed was 6.55 ± 2.11% and 15.00 ± 1.30% for IV-2 and IV-3 of CR, respectively, whereas IV-1 showed negligible inhibition (1.32 ± 1.10%) in heart rate at the end of 4 hrs. E_{max} attained by IV-1 and IV-2 were significantly lower than that of IV-3 (P < 0.05). A significant decrease in T_{50%} values was observed for IV-3 when compared with IV-2 and IV-1 (P < 0.05), whereas IV-1 and IV-2 showed a difference in T_{50%} values, which was not significant (P > 0.05). Time to produce maximal percent inhibition in isoprenaline effect by IV-3 was identical with the IV-1 or IV-2.

Table 3: Residence time of mucoadhesive buccal patch containing carvedilol

| Patch code | Residence time (hrs) |
|------------|----------------------|
| CC-1       | 10.0±2.44            |
| CC-2       | 12.0±0.63            |
| CC-3       | 12.5±0.18            |
| SC-1       | 6.5±3.1              |
| SC-2       | 8.0±0.55             |
| SC-3       | 11.0±0.42            |
| PC-1       | 7.0±2.3              |
| PC-2       | 11.5±0.11            |
| PC-3       | 13.5±0.58            |

Table 4: Calculated CR release kinetic parameters of all formulations containing carvedilol

| Patch code | Zero order r^2 value | First order r^2 value | Higuchi model | Korsmeyer-peppas model | N value |
|------------|----------------------|-----------------------|---------------|------------------------|---------|
| CC-1       | 0.950               | 0.9524                | 0.9038        | 0.9733                  | 0.3620  |
| CC-2       | 0.995               | 0.9160                | 0.9280        | 0.9832                  | 0.2960  |
| CC-3       | 0.980               | 0.9519                | 0.9469        | 0.9938                  | 0.3407  |
| SC-1       | 0.987               | 0.8556                | 0.8814        | 0.940                   | 0.3747  |
| SC-2       | 0.986               | 0.8505                | 0.8570        | 0.9839                  | 0.4716  |
| SC-3       | 0.968               | 0.9496                | 0.9188        | 0.9905                  | 0.3378  |
| PC-1       | 0.997               | 0.8916                | 0.8948        | 0.9915                  | 0.4404  |
| PC-2       | 0.993               | 0.8836                | 0.8749        | 0.9932                  | 0.419   |
| PC-3       | 0.989               | 0.8641                | 0.8740        | 0.9984                  | 0.5287  |

CR: Carvedilol

Figure 2: Residence time of mucoadhesive buccal patch containing carvedilol

Figure 3: In-vitro cumulative % release of CR from various buccal patches in phosphate buffer pH 6.8 at 37 ± 0.5°C
Figure 4: Scanning electron micrographs of optimized buccal patches (a) CC-2 (b) SC-3 (c) PC-2

Table 5: Percent inhibition in isoprenaline-induced heart rate after intravenous administration of CR

| Route of administration | Batch code | Dose (µg/kg) | Percent inhibition in heart rate (mean±SD) (n=3) | Time (min) |
|-------------------------|------------|--------------|-----------------------------------------------|------------|
|                         |            |              | 5          | 30         | 60          | 120         | 180         | 240         |
| i.v                     | IV-1       | 100          | 52.75±5.40 | 39.65±2.20 | 16.02±1.65  | 8.41±0.89   | 2.89±2.44   | 1.32±1.10   |
| i.v                     | IV-2       | 200          | 72.33±1.20 | 58.70±4.40 | 33.88±1.02  | 17.38±2.10  | 9.85±2.48   | 6.55±2.11   |
| i.v                     | IV-3       | 300          | 89.80±2.50 | 75.42±3.02 | 56.24±1.90  | 40.25±3.42  | 29.27±2.72  | 15.00±1.30  |
| Placebo, i.v.           | IV Normal Saline | -4.75     | -5.25      | -1.75      | 2.00        | -2.75       | -2.25       |

CR: Carvedilol, SD: Standard deviation

Oral administration of CR
The effect of oral (OS) CR on the isoprenaline-induced tachycardia in rabbits is shown in Table 6. Like IV, oral solution of CR also showed dose-dependent percent inhibition in isoprenaline-induced heart rate. CR oral solution at doses of 1 mg/kg (OS-1), 2 mg/kg (OS-2), and 4 mg/kg (OS-3) produced 69.95 ± 1.24, 85.10 ± 0.90, and 96.40 ± 2.20% inhibition, respectively, at 15 min. About 76% inhibition was observed with OS-3 dose at the end of 2 hrs, whereas about 68% and 28% inhibition was observed at the end of 2 hrs with OS-2 and OS-1, respectively. The inhibitory effect gradually decreased, and at the end of 8 hrs, the effect observed was 37.50 ± 0.95 and 29.72 ± 1.28 for OS-2 and OS-3 doses of CR, respectively, whereas with OS-1, the inhibitory effect (4.85 ± 1.85) was observed at the end of 6 hrs. The calculated pharmacodynamic parameters after oral administration of CR show that the $T_{\text{max}}$ values for all oral doses of CR were found to be 15 min. $T_{\text{max}}$ values for OS-1, OS-2, and OS-3 showed a difference that was not statistically significant ($P < 0.05$).

Buccal administration of CR
Table 7 presents the pharmacodynamic effect of buccal patches (CC-2, SC-3, and PC-2). The patches CC-2, SC-3, and PC-2 showed maximum inhibitory effect i.e. 50.52 ± 2.44, 27.02 ± 2.82, and 32.92 ± 2.80% within one hour and reached steady state inhibitory effect after 2 hrs. The steady state inhibitory effect was maintained around 35% (CC-2), 21% (SC-3), and 28% (PC-2) until the device was removed at the end of 6 hrs. After removal of the device, the effect started to decline and reached 3.70 ± 1.32%, 3.90 ± 1.20%, and 6.57 ± 1.42% for CC-2, SC-3, and for PC-3, 2 hrs after removal of device. $T_{0.5}$ inhibitory effect was not reached by the different patches. The relative % bioavailability of patches CC-2, SC-3, and PC-2 when compared to oral dose 2 mg/kg (OS-1) was found to be 160.72, 164.50, and 162.65%, respectively.

DISCUSSION
The FTIR spectra of carvedilol, chitosan, NaCMC, PVA, and drug-loaded patches showed no evidence of interaction as all the major peaks were found intact or exhibited very minor shift in frequencies. In the DSC study, the thermal peak of carvedilol shows that the drug was in pure form. The peak
61°C of chitosan is due to presence of moisture in the polymer. For PVA 215°C and for NaCMC 332°C was the melting point of polymer. The DSC thermogram of carvedilol, chitosan, NaCMC, PVA, and drug-loaded patches showed no evidence of interaction as all the major peaks were found intact or exhibited very minor shift in frequencies.

In evaluation of physiochemical properties, it was found that the content of drug present in the entire patch and thickness of all the patches was almost same. On the bases of weight variation results, it was observed that the weight of the patches increases as the concentration of the polymer increased. The pH of the patches was almost same as of salivary pH (5.5 - 7.0); they did not produce any local irritation on mucosal surface. All the patches show good flexibility because the folding endurance of all the patches was more than 300.

The values of % swelling decrease as the concentration of the polymer increase. The maximum value was 51.00 ± 0.47 for CC-1, and the least value was 8.7 ± 0.21 for CC-3 patch.

Residence time property was polymer-dependent because, as the concentration of the polymer increases, the residence time also increases.

By using the Korsmeyer-Peppas model equation, the n values were obtained between 0.2316 and 0.5000 for all formulations. These values are characteristic of Fickian diffusion. In this context, the results obtained from fitting the data in Koresmeyer-Peppas and zero order kinetics also supported the theory that the release of the drug from the patches was by a diffusion dominated.

The SEM photograph indicates the uniform dispersion of polymeric solution with drug molecules. We compared the i.v, oral, and buccal administration of drug in case of in-vivo bioavailability study; the buccal patches showed significantly greater inhibitory effect on isoprenaline-induced tachycardia.

### CONCLUSION

Overall, from the present study, carried out on carvedilol buccal patches prepared from variable amount of chitosan, NaCMC, and PVA, we concluded that the buccal patches prepared using chitosan, NaCMC, and PVA were found to have good physical characteristics. In the present study, patches showed significantly greater inhibitory effect on isoprenaline-induced tachycardia.

Lastly, we concluded that, buccal patches of chitosan, NaCMC, and PVA containing Carvedilol meet the ideal requirement for the delivery of cardiovascular drugs and inhibits the isoprenaline tachycardia.

### REFERENCES

1. Studzinska AM, Kijenska E, Tomasz C. Electroosmotic flow as a result of buccal iontophoresis: Buccal mucosa properties. Eur J Pharm Biopharm 2009;72:595-9.
2. Puthli SP, Dixit RP. Oral strip technology: Overview and future potential. J Control Release 2009;120:108-20.
3. Boddupalli BM, Mohammed ZN, Nath RA, Banji D. Mucoadhesive drug delivery system: An overview. J Adv Pharm Technol Res 2010;1:381-7.
4. Shakya P, Madhav NV, Shakya AK, Singh K. Orotransmucosal drug delivery systems: A review. J Adv Pharm Technol Res 2010;1:381-7.
5. Giannola LI, Caro VD, Giandalia G, Siragusa MG, Tripodo C, Campisi G. Release of nalbuphine on buccal mucosa: Permeation studies, histological aspects and matrix system design. Eur J Pharm Biopharm 2007;67:425-33.
6. Scholz OA, Wolff A, Schmacher A, Giannola LI. Drug delivery
from the cavity: Focus on a novel mechatronic delivery device. Drug Discov Today 2008;13:247-53.

7. Khanna R, Agarwal SD, Ahuja A. Mucoadhesive buccal drug delivery: A potential alternative to conventional therapy. Indian J Pharm Sci 1998;60:1-11.

8. Amir H, Shojaci RK, Chang C, Xiaodiguo AB, Couch RA. Systemic drug delivery via the buccal mucosal route. Pharm Tech 2001;2:1-27.

9. Hoogstraate AJ, Senel S, Cullander C, Verhoef J, Junginger HE, Bodde HE. Effects of bile salts on transport rates and routes of FTIC-labelled compounds across porcine buccal epithelium. J Control Release 1996;40:211-21.

10. Hao J, Heng PW. Buccal delivery systems. Drug Dev Ind Pharm 2003;29:821-2.

11. Jain NK. Controlled and Novel Drug Delivery. 1st ed II Vol. New Delhi: Published by CBS Publishers and Distributors; 1997. p. 52-61.

12. Yamahara H, Takehikosuzuki MM, Noda KK, Samejima MY. In situ perfusion system for oral mucosal absorption in dogs. J Pharm Sci 1990;79:4-6.

13. Kumar A, Phatarpekar V, Pathak N, Padhee K, Garg M. Formulation development and evaluation of Carvedilol bioerodable buccal mucoadhesive patches. Pharm Glob 2011;3:1-5.

14. Sevdsenel J, Hincal AA. Drug permeation enhancement via buccal route: Possibilities and limitations. J Control Release 2001;72:133-44.

15. Edsman K, Hagerstrom H. Pharmaceutical applications of mucoadhesion for the non-oral routes. J Pharm Pharmacol 2005;57:3-9.

16. Rao M, Vani G, Bala RR. Design and evaluation of mucoadhesive drug delivery systems. Indian Drugs 1980;35:112-5.

17. Madgulkar A, Kadam S, Pokharkar V. Development of buccal adhesive tablet with prolonged antifungal activity: Optimization and ex-vivo deposition studies. Indian J Pharm Sci 2009;71:290-4.

18. Charde S, Mudgal M, Kumar L, Saha R. Development and evaluation of buccoadhesive controlled release tablets of lercanidipine. AAPS Pharm Sci Tech 2008;9:182-90.

19. Cilurzo F, Cupone IE, Minghetti P, Selmin F, Montanari L. Fast dissolving films made of maltodextrins. Eur J Pharm Biopharm 2008;70:895-600.

20. Veillard MM, Longer MA, Martens T, Robinson JR. Preliminary studies of oral mucosal delivery of peptide drugs. J Control Release 1987;6:123-8.

21. Lee HJ, Kim SH, Lee SH. Rapid and sensitive carvedilol assay in human plasma using a high performance liquid chromatography with mass spectrometer detection employed for a bioequivalence study. Am J Anal Chem 2010;1:135-43.

22. Mitra AK, Alur HH. Peptides and Protein- Buccal Absorption, Encyclopedia of Pharmaceutical technology. Marcel Dekker Inc. Edition; 2001. p. 2081-3.

23. Doijad RC, Manve FV, Malleswara R, Patel PS. Buccoadhesive drug delivery system of Isosorbide dinitrate: Formulation and evaluation. Indian J Pharm Sci 2006;68:744-8.

24. Nagaich U, Chaudhary V, Sharma P, Yadav A. Formulation and Development of metoprolol tartrate bucco-adhesive films. Pharm Res 2009;1:41-3.

25. Alagusundaram M, Madhusudhana CC, Dhachinamoorthi D. Development and evaluation of Novel-trans-buccoadhesive films of Femotidine. J Adv Pharm Technol Res 2011;2:17-23.

26. Ahmad FJ, Sahni J, Khar RK. Design and in-vitro characterization of buccoadhesive drug delivery system of Insulin. Indian J Pharm Sci 2008;70:61-5.

27. Ismail FA, Nafee NA, Boraie NA, Mortada LM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm 2003;53:199-212.

28. Nappinnai M, Chandanbala R, Balajiiranjan R. Formulation and evaluation of Nitrendipine buccal films. Indian J Pharm Sci 2008;70:631-5.

29. Akpa PA, Attama AA, Onugwu LE, Igwilo G. Novel buccoadhesive delivery system of hydrochlorothiazide formulated with ethyl cellulosehydroxypropyl methylcellulose interpolymer complex. Sci Res Essay 2008;3:343-7.

30. Swamy PV, Shilpa H, Shirshand SB, Gada SN, Kinagi MB. Role of cogrinding in enhancing the in vitro dissolution characteristics of carvedilol. Int J Pharm Sci Res 2010;1:232-7.

How to cite this article: Verma N, Chattopadhyay P. Effect of novel mucoadhesive buccal patches of carvedilol on isoprenaline-induced tachycardia. J Adv Pharm Technol Res 2014;5:596-103.

Source of Support: Nil, Conflict of Interest: Nil.